Cargando…

Universal protection against influenza viruses by multi-subtype neuraminidase and M2 ectodomain virus-like particle

Annual influenza vaccination is recommended to update the variable hemagglutinin antigens. Here, we first designed a virus-like particle (VLP) displaying consensus multi-neuraminidase (NA) subtypes (cN1, cN2, B cNA) and M2 ectodomain (M2e) tandem repeat (m-cNA-M2e VLP). Vaccination of mice with m-cN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Ki-Hye, Li, Zhuo, Bhatnagar, Noopur, Subbiah, Jeeva, Park, Bo Ryoung, Shin, Chong Hyun, Pushko, Peter, Wang, Bao-Zhong, Kang, Sang-Moo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9409530/ https://www.ncbi.nlm.nih.gov/pubmed/36006890 http://dx.doi.org/10.1371/journal.ppat.1010755

Ejemplares similares

A chimeric thermostable M2e and H3 stalk-based universal influenza A virus vaccine
por: Subbiah, Jeeva, et al.
Publicado: (2022)

Adjuvant Effects of a New Saponin Analog VSA-1 on Enhancing Homologous and Heterosubtypic Protection by Influenza Virus Vaccination
por: Bhatnagar, Noopur, et al.
Publicado: (2022)

Heterologous Prime-Boost Vaccination with Inactivated Influenza Viruses Induces More Effective Cross-Protection than Homologous Repeat Vaccination
por: Bhatnagar, Noopur, et al.
Publicado: (2023)

Hemagglutinin virus-like particles incorporated with membrane-bound cytokine adjuvants provide protection against homologous and heterologous influenza virus challenge in aged mice
por: Park, Bo Ryoung, et al.
Publicado: (2023)

Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice
por: Kim, Ki-Hye, et al.
Publicado: (2021)

Thermostable H1 hemagglutinin stem with M2e epitopes provides broad cross-protection against group1 and 2 influenza A viruses
por: Subbbiah, Jeeva, et al.
Publicado: (2022)

Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin
por: Park, Bo Ryoung, et al.
Publicado: (2021)

Structure of the Parainfluenza Virus 5 (PIV5) Hemagglutinin-Neuraminidase (HN) Ectodomain
por: Welch, Brett D., et al.
Publicado: (2013)

Recombinant Live Attenuated Influenza Virus Expressing Conserved G-Protein Domain in a Chimeric Hemagglutinin Molecule Induces G-Specific Antibodies and Confers Protection against Respiratory Syncytial Virus
por: Jung, Yu-Jin, et al.
Publicado: (2020)

Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development
por: Pushko, Peter, et al.
Publicado: (2020)

Influenza Virus Neuraminidase: Structure and Function
por: Shtyrya, Y.A., et al.
Publicado: (2009)

Influenza Virus Neuraminidase Structure and Functions
por: McAuley, Julie L., et al.
Publicado: (2019)

Multiple Neuraminidase Containing Influenza Virus-like Particle Vaccines Protect Mice from Avian and Human Influenza Virus Infection
por: Kang, Hae-Ji, et al.
Publicado: (2022)

Neuraminidase in Virus-like Particles Contributes to the Protection against High Dose of Avian Influenza Virus Challenge Infection
por: Kang, Hae-Ji, et al.
Publicado: (2021)

Virus-Like Particles Containing the Tetrameric Ectodomain of Influenza Matrix Protein 2 and Flagellin Induce Heterosubtypic Protection in Mice
por: Wang, Li, et al.
Publicado: (2013)

Neuraminidase Subtyping of Avian Influenza Viruses with PrimerHunter-Designed Primers and Quadruplicate Primer Pools
por: Huang, Yanyan, et al.
Publicado: (2013)

Hemagglutinin and Neuraminidase Antibodies Are Induced in an Age- and Subtype-Dependent Manner after Influenza Virus Infection
por: Wong, Sook-San, et al.
Publicado: (2020)

Aurintricarboxylic acid inhibits influenza virus neuraminidase
por: Hung, Hui-Chen, et al.
Publicado: (2009)

Inherent Serum Inhibition of Influenza Virus Neuraminidases
por: Skarlupka, Amanda L., et al.
Publicado: (2021)

Bacterial Neuraminidase Rescues Influenza Virus Replication from Inhibition by a Neuraminidase Inhibitor
por: Nishikawa, Tomoko, et al.
Publicado: (2012)

Correction: Neuraminidase Subtyping of Avian Influenza Viruses with PrimerHunter-Designed Primers and Quadruplicate Primer Pools
por: Huang, Yanyan, et al.
Publicado: (2013)

In silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1
por: Tambunan, Usman Sumo Friend, et al.
Publicado: (2015)

Enhanced Immunogenicity of an Influenza Ectodomain Matrix-2 Protein Virus-like Particle (M2e VLP) Using Polymeric Microparticles for Vaccine Delivery
por: Gomes, Keegan Braz, et al.
Publicado: (2022)

Formation of virus-like particles from human cell lines exclusively expressing Influenza Neuraminidase
por: Lai, JCC, et al.
Publicado: (2011)

Influenza A Virus Hemagglutinin–Neuraminidase–Receptor Balance: Preserving Virus Motility
por: de Vries, Erik, et al.
Publicado: (2020)

Influenza Virus-like Particle-Based Hybrid Vaccine Containing RBD Induces Immunity against Influenza and SARS-CoV-2 Viruses
por: Bommireddy, Ramireddy, et al.
Publicado: (2022)

Fluorescence-based Neuraminidase Inhibition Assay to Assess the Susceptibility of Influenza Viruses to The Neuraminidase Inhibitor Class of Antivirals
por: Leang, Sook-Kwan, et al.
Publicado: (2017)

The Interplay between the Host Receptor and Influenza Virus Hemagglutinin and Neuraminidase
por: Byrd-Leotis, Lauren, et al.
Publicado: (2017)

Antibody Neutralization of an Influenza Virus that Uses Neuraminidase for Receptor Binding
por: Gentles, Lauren E., et al.
Publicado: (2020)

Phase Partitioning of influenza Virus Neuraminidase in a Model Membrane
por: Reza Arastoo, Mohammad, et al.
Publicado: (2021)

Monoclonal antibodies targeting the influenza virus N6 neuraminidase
por: Strohmeier, Shirin, et al.
Publicado: (2022)

An Update on mRNA-Based Viral Vaccines
por: Jeeva, Subbiah, et al.
Publicado: (2021)

Universal type/subtype-specific antibodies for quantitative analyses of neuraminidase in trivalent influenza vaccines
por: Xu, Kangwei, et al.
Publicado: (2018)

Towards Goals to Refine Prophylactic and Therapeutic Strategies Against COVID-19 Linked to Aging and Metabolic Syndrome
por: Shin, Chong-Hyun, et al.
Publicado: (2021)

Consecutive influenza surveillance of neuraminidase mutations and neuraminidase inhibitor resistance in Japan
por: Chong, Yong, et al.
Publicado: (2019)

Influenza M2 virus-like particle vaccination enhances protection in combination with avian influenza HA VLPs
por: Kang, Hae-Ji, et al.
Publicado: (2019)

Functional significance of the hemadsorption activity of influenza virus neuraminidase and its alteration in pandemic viruses
por: Uhlendorff, Jennifer, et al.
Publicado: (2009)

Vaccine-Induced Immunity Elicited by Microneedle Delivery of Influenza Ectodomain Matrix Protein 2 Virus-like Particle (M2e VLP)-Loaded PLGA Nanoparticles
por: Braz Gomes, Keegan, et al.
Publicado: (2023)

2752. Peptide Vaccines Utilizing Conserved Hemagglutinin, Neuraminidase, and Matrix Ectodomain Influenza Epitopes Demonstrate Functional Activity Against Group 1 and 2 Influenza Strains
por: Sei, Clara J, et al.
Publicado: (2019)

Influenza neuraminidase
por: Air, Gillian M.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_0g9bbhk4dseg4rad4r4hd6igmm